Net Sales Milestones. In consideration of the research and Development work to be performed by GlobeImmune under this Agreement, the following Net [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Sales threshold milestone payments will be paid, on a Program-by-Program basis, the first time in any Calendar Year that the total aggregate Net Sales of all Licensed Products containing a Celgene Development Compound in a particular Program in a Calendar Year by Celgene, its Affiliates and its Sublicensees in the Territory reach the amounts set forth in the table in this Section 6.2.5 below. Each payment will be made only once for each Program. [*] [* ] [*] [* ] [*] [* ]
Net Sales Milestones. Subject to the terms and conditions of this Agreement, including Section 7.4, within [***] after the end of the Calendar Quarter in which any of the following Milestone Events is achieved by or on behalf of AbbVie or its Affiliates or Sublicensees, AbbVie shall pay to Morphic the corresponding Milestone Payment with respect to such Milestone Event on an Included Target-by-Included Target basis in the Territory:
1. [***] [***]
2. [***] [***] Each Milestone Payment in this Section 7.2.3 shall be payable only upon the first achievement of the applicable Milestone Event by Licensed Products containing Licensed Compounds Directed to such Included Target and not for any other subsequent achievement by any additional Licensed Product(s) containing such Licensed Compounds. The maximum aggregate amount of Milestone Payments payable under this Section 7.2.3 by AbbVie with respect to Licensed Products for each Included Target is [***].
Net Sales Milestones. Licensee shall pay to Exelixis the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Licensee Territory in any period of four (4) consecutive Calendar Quarters first reach the values indicated in the table below. Once one of the values indicated in the table below is first reached and the corresponding Milestone Payment is paid by Licensee under this Section 9.4 (the “Previously Achieved Commercial Milestone”), the period of four (4) consecutive Calendar Quarters to be applied to determine the reaching of a subsequent Net Sales amount in the table below shall only start at the Calendar Quarter immediately following the fourth (4th) Calendar Quarter which served as the period to determine the reaching of the Net Sales amount triggering the Previously Achieved Commercial Milestone. For the avoidance of doubt, each payment in this Section 9.4 shall be payable once only, regardless of the number of times such milestone is subsequently achieved. Equal or exceed $[ * ] $[ * ] Equal or exceed $[ * ] $[ * ] Equal or exceed $[ * ] $[ * ] Equal or exceed $[ * ] $[ * ] Equal or exceed $[ * ] $[ * ]
Net Sales Milestones. Takeda shall pay, in accordance with Section 7.4, to Orexigen the applicable Net Sales threshold milestone payments set forth in the table in this Section 7.2.2, below, the first and only the first time during the Term that the total aggregate Net Sales of all Products (including all Indications and formulations of such Products) in any Calendar Year by Takeda, its Affiliates and its Sublicensees in the Territory reach or exceed the relevant amounts set forth in the table in this Section 7.2.2, below. Annual Calendar Year Net Sales for Products in the Territory in all Indications Payment [***] $[***] [***] $[***] [***] $[***] [***] $[***] [***] $[***] [***] $[***] [***] $[***] *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Net Sales Milestones. As set forth in more detail in the APA, if Hyperion exercises the Marketed Products Option and Ucyclyd does not exercise the Ammonul Option, then sales of Ammonul will be included when determining whether certain Net Sales milestones payments are due pursuant to the APA.
Net Sales Milestones. Section 9.4(b) is hereby deleted in its entirety and replaced with the following:
Net Sales Milestones. Xxxxxxx shall pay BN the following one time milestone payments for the first time that the following Net Sales milestones are achieved:
(1) [***] which shall be non-creditable and non-refundable, due within sixty (60) days from the date on which the aggregate Net Sales of all Licensed Components and Licensed Products for which a royalty is due hereunder exceeds [***]; and
(2) [***] which shall be non-creditable and non-refundable, due within sixty (60) days from the date on which the aggregate Net Sales of all Licensed Components and Licensed Products for which a royalty is due hereunder exceeds [***].
Net Sales Milestones. BSP shall pay to OncoMed the applicable one-time-only Net Sales threshold milestone payments set forth in the table in Exhibit 6.3.5, [***], within [***] after receipt of an invoice for such payment, which invoice shall issue no earlier than the first time that the total aggregate Net Sales [***] in a Calendar Year by BSP, its Affiliates and its Sublicensees in the Territory reach or exceed the relevant amounts set forth in the table in Exhibit 6.3.5.
Net Sales Milestones. Company shall pay Licensor the following one-time milestone payments upon sales of Products achieving the following Net Sales Events (whether such achievement is Company or its Sublicensees): When annual worldwide Net Sales for Products first exceeds [*]: [*] When annual worldwide Net Sales for such Licensed Product first exceeds [*]: [*] When annual worldwide Net Sales for such Licensed Product first exceeds [*]: [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Net Sales Milestones. 10.3.1 Subject to Section 10.3.2, on a Licensed Product-by-Licensed Product basis, Verve will pay Beam the following one-time payments when aggregate Net Sales of a Licensed Product that is not a Collaboration Product in a Calendar Year in the Territory first reach the respective thresholds indicated below:
10.3.2 Notwithstanding Section 10.3.1, on a Licensed Product-by-Licensed Product basis, with respect to any Licensed Product that is a Collaboration Product, Verve will pay Beam the following one-time payments when aggregate Net Sales of such Licensed Product outside the Collaboration Territory first reach the respective thresholds indicated below:
10.3.3 Verve will make any Net Sales threshold milestone payment payable with respect to a Calendar Year within [**] after the end of the applicable Calendar Year. The Net Sales threshold milestone payments set forth above are payable only once on the first achievement by each Licensed Product of the relevant threshold. No amounts shall be due under this Agreement for subsequent or repeated achievements of any milestone by the same Licensed Product. If more than one Net Sales threshold milestone is achieved in the same Calendar Year, Verve will pay to Beam all Net Sales threshold milestone payments achieved in such Calendar Year in accordance with this Section 10.3.3.
